| Literature DB >> 34830330 |
Francesca Potenza1,2, Maria Concetta Cufaro2,3, Linda Di Biase1,2, Valeria Panella4, Antonella Di Campli2,5, Anna Giulia Ruggieri1,2, Beatrice Dufrusine1,2, Elena Restelli6, Laura Pietrangelo2,7, Feliciano Protasi2,7, Damiana Pieragostino1,2, Vincenzo De Laurenzi1,2, Luca Federici1,2, Roberto Chiesa6, Michele Sallese1,2.
Abstract
Marinesco-Sjogren syndrome (MSS) is a rare multisystem pediatric disorder, caused by loss-of-function mutations in the gene encoding the endoplasmic reticulum cochaperone SIL1. SIL1 acts as a nucleotide exchange factor for BiP, which plays a central role in secretory protein folding. SIL1 mutant cells have reduced BiP-assisted protein folding, cannot fulfil their protein needs, and experience chronic activation of the unfolded protein response (UPR). Maladaptive UPR may explain the cerebellar and skeletal muscle degeneration responsible for the ataxia and muscle weakness typical of MSS. However, the cause of other more variable, clinical manifestations, such as mild to severe mental retardation, hypogonadism, short stature, and skeletal deformities, is less clear. To gain insights into the pathogenic mechanisms and/or adaptive responses to SIL1 loss, we carried out cell biological and proteomic investigations in skin fibroblasts derived from a young patient carrying the SIL1 R111X mutation. Despite fibroblasts not being overtly affected in MSS, we found morphological and biochemical changes indicative of UPR activation and altered cell metabolism. All the cell machineries involved in RNA splicing and translation were strongly downregulated, while protein degradation via lysosome-based structures was boosted, consistent with an attempt of the cell to reduce the workload of the endoplasmic reticulum and dispose of misfolded proteins. Cell metabolism was extensively affected as we observed a reduction in lipid synthesis, an increase in beta oxidation, and an enhancement of the tricarboxylic acid cycle, with upregulation of eight of its enzymes. Finally, the catabolic pathways of various amino acids, including valine, leucine, isoleucine, tryptophan, lysine, aspartate, and phenylalanine, were enhanced, while the biosynthetic pathways of arginine, serine, glycine, and cysteine were reduced. These results indicate that, in addition to UPR activation and increased protein degradation, MSS fibroblasts have profound metabolic alterations, which may help them cope with the absence of SIL1.Entities:
Keywords: BiP; autophagosome; fibroblast; neurodegenerative disease; pathway analysis; protein folding; unfolded protein response
Mesh:
Substances:
Year: 2021 PMID: 34830330 PMCID: PMC8620507 DOI: 10.3390/ijms222212449
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1UPR activation in MSS patient fibroblasts. (A,C) HF-CT (CT) and HF-MSS (MSS) cultured under standard growth conditions were analyzed by Western blotting to assess the expression of SIL1, ATF4, ATF6, and the phosphorylated form of EIF2α (A), BiP, ORP150, and PDI (C) as indicated. Immunoblots are representative of at least two independent experiments. Ponceau S staining of the blots is shown to control for equal protein loading. (B) XBP1 splicing was assessed by PCR. HF-CT (first lane) treated with 1 μM thapsigargin (Tg) for 6 h was used as a positive control. The higher and lower bands represent the unspliced (U) and spliced (S) forms of XBP1.
Figure 2LAMP1-positive structures increase in HF-MSS cells. (A) HF-CT (CT) and HF-MSS (MSS) were plated on glass coverslips, fixed in PFA 4%, and processed for immunofluorescence. Confocal images of cells immunostained for LAMP1 (green) and reacted with Hoechst 33342 (blue) to stain the nuclei. The merge of green and blue channels is represented in the third panel. A magnification of the squared area is also shown. White arrows indicate ring-like structures. Scale bar: 20 µm. (B) Quantification of total LAMP1 staining shown in A. * p < 0.05.
Figure 3Electron microscopy (EM) and immunoblot analysis of autophagic vacuoles. (A) Ultrastructural alterations in HF-MSS. Representative EM micrographs of HF-CT (a) and HF-MSS (c) cells. Details at higher magnification of the cytoplasm of HF-CT (b) and HF-MSS (d) cells. HF-MSS cells accumulate vacuoles containing large clusters of membranes (arrowheads) and multilamellar bodies (asterisks). Scale bars: a and c: 2 μm; b and d: 1 μm. (B) Upper graph, percentage of HF-CT and HF-MSS cells exhibiting vacuoles/multilamellar bodies (n = 100 cells/group); lower graph, average number of vacuoles/multilamellar bodies per cell calculated by considering only the cells showing such structures. Statistical significance Chi square test (lower) and t-test (upper) * p < 0.05. (C) HF-CT (CT) and HF-MSS (MSS) cultured under standard growth conditions were analyzed by Western blotting for the expression of p62/SQSTM1 (p62), LC3, and LAMP1. Immunoblots are representative of at least two independent experiments. Ponceau S staining of the blots is shown to control for equal protein loading.
Figure 4Proteomic analysis graphical networks. (A) Volcano Plot: Statistical analysis of differentially expressed proteins between HF-CT and HF-MSS cells, run by Perseus. LQF intensity of HF-MSS minus that of HF-CT was plotted against the negative logarithm of the p-values. (B) STRING network of proteins downregulated (left) and upregulated (right) in HF-MSS, confidence level set at 0.9. Squares indicate examples of clusters of interacting proteins involved in the indicated functions.
Selected biological processes altered in HF-MSS, based on Gene Ontology enrichment analysis.
| Term ID 1 | Term Description 2 | Observed Gene Count 3 | Background Gene Count 4 | False Discovery Rate 5 |
|---|---|---|---|---|
| GO:0016071 | mRNA metabolic process | 83 | 667 | 2.5 × 10−21 |
| GO:0000398 | mRNA splicing, via spliceosome | 45 | 284 | 6.16 × 10−15 |
| GO:0006397 | mRNA processing | 54 | 456 | 2.70 × 10−13 |
| GO:1903311 | regulation of mRNA metabolic process | 36 | 238 | 1.89 × 10−11 |
| GO:0043488 | regulation of mRNA stability | 21 | 113 | 4.54 × 10−8 |
| GO:0050684 | regulation of mRNA processing | 18 | 114 | 4.33 × 10−6 |
| GO:0048024 | regulation of mRNA splicing, via spliceosome | 15 | 77 | 4.38 × 10−6 |
| GO:0006413 | translational initiation | 30 | 142 | 1.17 × 10−12 |
| GO:0006412 | translation | 44 | 362 | 3.99 × 10−11 |
| GO:0006417 | regulation of translation | 38 | 327 | 3.73 × 10−9 |
| GO:0002181 | cytoplasmic translation | 15 | 57 | 1.90 × 10−7 |
| GO:0006446 | regulation of translational initiation | 8 | 71 | 0.0246 |
| GO:0006614 | SRP-dependent cotranslational protein targeting to membrane | 23 | 92 | 6.11 × 10−11 |
| GO:0016192 | vesicle-mediated transport | 139 | 1699 | 6.02 × 10−21 |
| GO:0060627 | regulation of vesicle-mediated transport | 30 | 480 | 0.0077 |
| GO:0006892 | post-Golgi vesicle-mediated transport | 9 | 83 | 0.0197 |
| GO:0055114 | oxidation-reduction process | 94 | 932 | 4.04 × 10−9 |
| GO:0015980 | energy derivation by oxidation of organic compounds | 17 | 217 | 0.0112 |
| GO:0044281 | small molecule metabolic process | 134 | 1779 | 1.21 × 10−17 |
| GO:0062012 | regulation of small molecule metabolic process | 21 | 332 | 0.0272 |
1 Unique seven-digit identifier prefixed by GO. 2 Textual description of the term. 3 Number of genes linked to that GO term in the input list. 4 Number of genes linked to a GO term in the entire background set. 5 Expected ratio of the number of false positive classifications (false discoveries) to the total number of positive classifications.
Selected molecular functions altered in HF-MSS, based on Gene Ontology enrichment analysis.
| Term ID 1 | Term Description 2 | Observed Gene Count 3 | Background Gene Count 4 | False Discovery Rate 5 |
|---|---|---|---|---|
| GO:0003723 | RNA binding | 86 | 850 | 2.57 × 10−17 |
| GO:0003729 | mRNA binding | 36 | 198 | 2.76 × 10−13 |
| GO:0003727 | single-stranded RNA binding | 13 | 80 | 0.00011 |
| GO:0003725 | double-stranded RNA binding | 11 | 70 | 0.00058 |
| GO:0019843 | rRNA binding | 10 | 60 | 0.00079 |
| GO:0008135 | translation factor activity, RNA binding | 11 | 84 | 0.0021 |
| GO:0000049 | tRNA binding | 8 | 56 | 0.0079 |
| GO:0061980 | regulatory RNA binding | 5 | 34 | 0.0424 |
| GO:0016491 | oxidoreductase activity | 75 | 716 | 8.70 × 10−16 |
| GO:0016860 | intramolecular oxidoreductase activity | 12 | 47 | 5.01 × 10−6 |
| GO:0000166 | nucleotide binding | 134 | 2097 | 2.45 × 10−12 |
| GO:0017076 | purine nucleotide binding | 108 | 1865 | 1.36 × 10−7 |
| GO:0030554 | adenyl nucleotide binding | 79 | 1524 | 0.00039 |
| GO:0008092 | cytoskeletal protein binding | 71 | 882 | 4.82 × 10−10 |
| GO:0046961 | proton-transporting ATPase activity, rotational mechanism | 9 | 21 | 4.97 × 10−6 |
| GO:0008553 | proton-exporting ATPase activity, phosphorylative mechanism | 9 | 23 | 8.55 × 10−6 |
| GO:0015078 | proton transmembrane transporter activity | 12 | 120 | 0.0082 |
| GO:0005178 | integrin binding | 19 | 122 | 2.30 × 10−6 |
| GO:0050839 | cell adhesion molecule binding | 24 | 200 | 3.68 × 10−6 |
| GO:0098634 | cell-matrix adhesion mediator activity | 3 | 7 | 0.0229 |
1 Unique seven-digit identifier prefixed by GO. 2 Textual description of the term. 3 Number of genes linked to that GO term in the input list. 4 Number of genes linked to a GO term in the entire background set. 5 Expected ratio of the number of false positive classifications (false discoveries) to the total number of positive classifications.
Selected cellular components altered in HF-MSS, based on Gene Ontology enrichment analysis.
| Term ID 1 | Term Description 2 | Observed Gene Count 3 | Background Gene Count 4 | False Discovery Rate 5 |
|---|---|---|---|---|
| GO:0043226 | organelle | 566 | 12432 | 1.37 × 10−50 |
| GO:0043229 | intracellular organelle | 560 | 12193 | 3.30 × 10−50 |
| GO:0043227 | membrane-bounded organelle | 516 | 11244 | 1.07 × 10−37 |
| GO:0005783 | endoplasmic reticulum | 120 | 1796 | 9.40 × 10−13 |
| GO:0005788 | endoplasmic reticulum lumen | 30 | 299 | 1.86 × 10−6 |
| GO:0005793 | endoplasmic reticulum-Golgi intermediate compartment | 13 | 113 | 0.00095 |
| GO:0031982 | vesicle | 173 | 2318 | 4.41 × 10−24 |
| GO:0031410 | cytoplasmic vesicle | 166 | 2226 | 6.49 × 10−23 |
| GO:0099503 | secretory vesicle | 96 | 948 | 1.62 × 10−20 |
| GO:0030139 | endocytic vesicle | 35 | 275 | 8.75 × 10−10 |
| GO:0045335 | phagocytic vesicle | 23 | 122 | 2.25 × 10−9 |
| GO:0042470 | melanosome | 35 | 105 | 1.55 × 10−20 |
| GO:1990904 | ribonucleoprotein complex | 89 | 770 | 2.33 × 10−22 |
| GO:0030532 | small nuclear ribonucleoprotein complex | 11 | 67 | 0.00021 |
| GO:0005773 | vacuole | 74 | 682 | 4.05 × 10−17 |
| GO:0005775 | vacuolar lumen | 30 | 172 | 2.47 × 10−11 |
| GO:0005774 | vacuolar membrane | 31 | 311 | 1.36 × 10−6 |
| GO:0005764 | lysosome | 67 | 582 | 1.24 × 10−16 |
| GO:0015629 | actin cytoskeleton | 42 | 432 | 1.75 × 10−8 |
| GO:0032432 | actin filament bundle | 12 | 57 | 1.38 × 10−5 |
1 Unique seven-digit identifier prefixed by GO. 2 Textual description of the term. 3 Number of genes linked to that GO term in the input list. 4 Number of genes linked to a GO term in the entire background set. 5 Expected ratio of the number of false positive classifications (false discoveries) to the total number of positive classifications.
Selected altered pathways in HF-MSS, based on KEGG enrichment analysis.
| Term ID 1 | Term Description 2 | Observed Gene Count 3 | Background Gene Count 4 | False Discovery Rate 5 |
|---|---|---|---|---|
| hsa03040 | spliceosome | 26 | 130 | 3.14 × 10−10 |
| hsa03010 | ribosome | 21 | 130 | 3.48 × 10−7 |
| hsa03013 | RNA transport | 14 | 159 | 0.0074 |
| hsa04145 | phagosome | 26 | 145 | 1.35 × 10−9 |
| hsa04142 | lysosome | 24 | 123 | 1.39 × 10−9 |
| hsa01100 | metabolic pathways | 99 | 1250 | 1.52 × 10−13 |
| hsa00020 | citrate cycle (TCA cycle) | 9 | 30 | 7.00 × 10−5 |
| hsa01212 | fatty acid metabolism | 10 | 48 | 0.00024 |
| hsa01230 | biosynthesis of amino acids | 11 | 72 | 0.00075 |
| hsa00010 | glycolysis/Gluconeogenesis | 10 | 68 | 0.0017 |
| hsa00030 | pentose phosphate pathway | 5 | 30 | 0.0259 |
1 Unique identifier for each KEGG object which takes the form of a prefix followed a five-digit number. 2 Textual description of the term. 3 Number of genes linked to that KEGG term in the input list. 4 Number of genes linked to a KEGG term in the entire background set. 5 Expected ratio of the number of false positive classifications (false discoveries) to the total number of positive classifications.
Selected canonical pathways altered in HF-MSS, based on Ingenuity Pathway Analysis.
| Ingenuity Canonical Pathway 1 | −log ( | z-Score 3 |
|---|---|---|
| phagosome maturation | 14.6 | |
| EIF2 signaling | 14 | −2.357 |
| caveolar-mediated endocytosis signaling | 7.97 | |
| fatty acid β-oxidation I | 7.88 | 2.53 |
| TCA cycle II (Eukaryotic) | 6.89 | 2.121 |
| isoleucine degradation I | 6.83 | 2.236 |
| mitochondrial dysfunction | 6.78 | |
| valine degradation I | 4.99 | 2.236 |
| tryptophan degradation III (Eukaryotic) | 4.49 | 1.342 |
| spliceosomal cycle | 3.51 | −2.646 |
| tRNA charging | 2.43 | −1.342 |
1 Textual description of the term. 2 Negative logarithm of p-value. 3 Also called standard score, is the number of standard deviations by which the value of a raw score is above or below the mean value of what is being observed or measured.
Selected disease or functions that are predicted to be increased or decreased on the basis of differential proteins in HF-MSS, based on Ingenuity Pathway Analysis.
| Disease or Functions Annotation 1 | z-Score 2 | Predicted Activation State 3 | |
|---|---|---|---|
| fatty acid metabolism | 4.57 × 10−12 | 2.017 | Increased |
| cellular homeostasis | 5.29 × 10−11 | 2.129 | Increased |
| cell death of tumor cell lines | 8.41 × 10−24 | 2.15 | Increased |
| endocytosis by eukaryotic cells | 5.24 × 10−11 | 2.311 | Increased |
| metabolism of glycosphingolipid | 0.00000134 | 2.387 | Increased |
| cell death of tumor cells | 1.13 × 10−13 | 2.416 | Increased |
| sensitivity of cells | 0.000000386 | 2.56 | Increased |
| phagocytosis | 3.93 × 10−8 | 2.708 | Increased |
| phagocytosis of cells | 0.000000438 | 2.714 | Increased |
| degradation of extracellular matrix | 7.31 × 10−8 | 2.905 | Increased |
| cell death of cancer cells | 1.17 × 10−10 | 2.995 | Increased |
| cell death of osteosarcoma cells | 1.76 × 10−12 | 3.545 | Increased |
| homologous recombination | 9.48 × 10−9 | −3.637 | Decreased |
| accumulation of lipid | 2.49 × 10−9 | −3.636 | Decreased |
| homologous recombination of cells | 5.85 × 10−9 | −3.499 | Decreased |
| glucose metabolism disorder | 0.00000102 | −3.279 | Decreased |
| DNA recombination | 6.51 × 10−9 | −3.235 | Decreased |
| motor dysfunction or movement disorder | 1.01 × 10−18 | −2.934 | Decreased |
| movement Disorders | 9.11 × 10−19 | −2.666 | Decreased |
| lysosomal storage disease | 2.68 × 10−10 | −2.591 | Decreased |
| repair of DNA | 0.000000166 | −2.545 | Decreased |
| cell death of breast cancer cell lines | 9.12 × 10−8 | −2.374 | Decreased |
| astrocytosis | 0.00000147 | −2.219 | Decreased |
| degeneration of central nervous system | 8.66 × 10−9 | −2.218 | Decreased |
| neurodegeneration | 0.000000465 | −2.185 | Decreased |
| degeneration of nervous system | 0.000000827 | −2.128 | Decreased |
| amyloidosis | 7.3 × 10−13 | −2.08 | Decreased |
| degeneration of brain | 1.46 × 10−8 | −2.032 | Decreased |
1 Textual description of the term. 2 Also called standard score, is the number of standard deviations by which the value of a raw score is above or below the mean value of what is being observed or measured. 3 Prediction based on the observed gene expression changes in the dataset.
Figure 5Fluorescence microscopy of representative DE proteins. (A) HF-CT (CT) and HF-MSS (MSS) were plated on glass coverslips, fixed in PFA 4%, and processed for immunofluorescence. Confocal images of cells stained for CNX (red) and NCL (green) are shown. The merge of green and red channels is shown in the third panel. Scale bar: 20 µm. (B) Quantification of total CNX staining and the number of NCL-positive nucleoli/cell of the experiment shown in A. Blue and red bars indicate HF-CT and HF-MSS, respectively. ** p < 0.01.
Figure 6Fluorescence microscopy validation of proteomic analysis. (A) HF-CT (CT) and HF-MSS (MSS) were plated on glass coverslips, fixed in PFA 4%, and processed for immunofluorescence. Confocal images of cells stained for PDI (green) and NPM (red) are shown. The merge of green and red signal is also shown. Scale bar: 20 µm. (B) Quantification of total PDI staining and the number of NPM-positive nucleoli/cell of the experiment shown in A. Blue and red bars indicate HF-CT and HF-MSS, respectively. **** p < 0.0001.
Figure 7Western blot validation of proteomic analysis. (A,B) HF-CT (CT) and HF-MSS (MSS) cultured under standard growth conditions were analyzed by Western blotting to assess the expression of NPM, NCL, NES, CAV-1, ANXA-5, and CTHRC1 as indicated. The proteins downregulated or upregulated in HF-MSS are shown in A and B, respectively. Immunoblots are representative of at least two independent experiments. Ponceau S staining of the blots is shown to control for equal protein loading.